[go: up one dir, main page]

MX2018004071A - POLYPEPTIDES AS ANTIBODIES AND USES OF THE SAME. - Google Patents

POLYPEPTIDES AS ANTIBODIES AND USES OF THE SAME.

Info

Publication number
MX2018004071A
MX2018004071A MX2018004071A MX2018004071A MX2018004071A MX 2018004071 A MX2018004071 A MX 2018004071A MX 2018004071 A MX2018004071 A MX 2018004071A MX 2018004071 A MX2018004071 A MX 2018004071A MX 2018004071 A MX2018004071 A MX 2018004071A
Authority
MX
Mexico
Prior art keywords
seq
antibodies
chain variable
variable region
polypeptides
Prior art date
Application number
MX2018004071A
Other languages
Spanish (es)
Inventor
Juhani Lamminmäki Urpo
Ann- Christin Malmborg Hager Cecilia
SJÖSTRÖM Kjell
Erik Strand Sven-
Thuy Tran Amanda
Axelsson Anders
Original Assignee
Fredax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1517550.8A external-priority patent/GB201517550D0/en
Priority claimed from GBGB1519105.9A external-priority patent/GB201519105D0/en
Application filed by Fredax Ab filed Critical Fredax Ab
Publication of MX2018004071A publication Critical patent/MX2018004071A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/57555—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención proporciona polipéptidos como anticuerpos con especificidad de unión por antígeno específico de próstata (PSA), donde el polipéptido como anticuerpo comprende (a) una región variable de cadena pesada que comprende las secuencias de aminoácidos de SEQ ID NO: 1 y SEQ ID NO: 2 y SEQ ID NO: 3 y/o (b) una región variable de cadena ligera que comprende las secuencias de aminoácidos de SEQ ID NO: 4 y SEQ ID NO: 5 y SEQ ID NO: 6, y en donde la región variable de cadena pesada y la región variable de cadena ligera comprenden secuencias de aminoácidos estructurales de uno o más anticuerpos humanos. La invención también proporciona el uso de dichos polipéptidos como anticuerpos en el diagnóstico y tratamiento del cáncer de próstata.The present invention provides polypeptides as antibodies with binding specificity for prostate specific antigen (PSA), wherein the polypeptide as antibody comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2 and SEQ ID NO: 3 and / or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 5 and SEQ ID NO: 6, and wherein the heavy chain variable region and light chain variable region comprise structural amino acid sequences of one or more human antibodies. The invention also provides the use of said polypeptides as antibodies in the diagnosis and treatment of prostate cancer.

MX2018004071A 2015-10-05 2016-10-04 POLYPEPTIDES AS ANTIBODIES AND USES OF THE SAME. MX2018004071A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1517550.8A GB201517550D0 (en) 2015-10-05 2015-10-05 Antibody polypeptides and uses thereof
GBGB1519105.9A GB201519105D0 (en) 2015-10-29 2015-10-29 Antibody polypeptides and uses thereof
PCT/EP2016/073684 WO2017060247A1 (en) 2015-10-05 2016-10-04 Humanized anti psa (5a10) antibodies

Publications (1)

Publication Number Publication Date
MX2018004071A true MX2018004071A (en) 2018-11-09

Family

ID=57113327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004071A MX2018004071A (en) 2015-10-05 2016-10-04 POLYPEPTIDES AS ANTIBODIES AND USES OF THE SAME.

Country Status (17)

Country Link
US (2) US11332543B2 (en)
EP (2) EP3359189B1 (en)
JP (1) JP6916797B2 (en)
KR (1) KR102783861B1 (en)
CN (1) CN108136013B (en)
AU (1) AU2016334715B2 (en)
CA (1) CA2998818A1 (en)
DK (1) DK3359189T3 (en)
ES (1) ES2880682T3 (en)
IL (1) IL258189B2 (en)
LT (1) LT3359189T (en)
MX (1) MX2018004071A (en)
PL (1) PL3359189T3 (en)
PT (1) PT3359189T (en)
RU (1) RU2753677C2 (en)
WO (1) WO2017060247A1 (en)
ZA (1) ZA201802019B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102783861B1 (en) * 2015-10-05 2025-03-21 프레닥스 에이비 Humanized anti-PSA (5A10) antibody
PE20191716A1 (en) 2017-02-08 2019-12-05 Bristol Myers Squibb Co MODIFIED RELAXIN POLYPEPTIDES INCLUDING A PHARMACOKINETIC ENHANCER AND THEIR USES
JP2023512214A (en) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド Joint optimization of radionuclides and external beam radiotherapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (en) 1985-07-12 1989-05-29 Aake Rikard Lindahl SET TO MANUFACTURE SPHERICAL POLYMER PARTICLES
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
FI20002127A0 (en) * 2000-09-27 2000-09-27 Artic Partners Oy Ab New antibody, immunoassay and method for the detection of cancer in the prostate
SI1772465T1 (en) 2005-01-05 2009-06-30 F Star Biotech Forsch & Entw Synthetic immunoglobulin domains with modified binding properties in regions of the molecule that differ from the complementarity of the receiving regions
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
EP2303332B1 (en) * 2008-07-15 2014-12-31 Genentech, Inc. Anthracycline conjugates, process for their preparation and their use as antitumor compounds
JP2010004895A (en) 2009-10-13 2010-01-14 Hiroshima Univ Method for preparation of humanized chicken antibody
KR102232811B1 (en) * 2011-10-28 2021-03-29 프레닥스 에이비 Therapeutic agents and uses thereof
RU2537263C2 (en) 2012-10-22 2014-12-27 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" Method of screening and monitoring cancerous diseases and kit therefor (versions)
GB2520353A (en) 2013-11-19 2015-05-20 Fredax Ab Antibody polypeptides and uses thereof
CA2944001C (en) 2014-03-28 2023-08-15 Opko Diagnostics, Llc Compositions and methods related to diagnosis of prostate cancer
KR102783861B1 (en) * 2015-10-05 2025-03-21 프레닥스 에이비 Humanized anti-PSA (5A10) antibody

Also Published As

Publication number Publication date
IL258189B (en) 2022-11-01
AU2016334715A1 (en) 2018-04-12
IL258189A (en) 2018-05-31
RU2753677C2 (en) 2021-08-19
JP2018531045A (en) 2018-10-25
ZA201802019B (en) 2021-09-29
PT3359189T (en) 2021-07-19
KR102783861B1 (en) 2025-03-21
JP6916797B2 (en) 2021-08-11
RU2018115734A (en) 2019-11-07
EP3359189B1 (en) 2021-06-23
EP3359189A1 (en) 2018-08-15
ES2880682T3 (en) 2021-11-25
EP3922265A1 (en) 2021-12-15
DK3359189T3 (en) 2021-07-05
US11332543B2 (en) 2022-05-17
PL3359189T3 (en) 2021-12-20
HK1258674A1 (en) 2019-11-15
CA2998818A1 (en) 2017-04-13
RU2018115734A3 (en) 2020-03-27
IL258189B2 (en) 2023-03-01
US20180273634A1 (en) 2018-09-27
CN108136013B (en) 2023-04-18
CN108136013A (en) 2018-06-08
WO2017060247A1 (en) 2017-04-13
AU2016334715B2 (en) 2023-02-02
KR20180053756A (en) 2018-05-23
US20220242969A1 (en) 2022-08-04
LT3359189T (en) 2021-07-26
US12441808B2 (en) 2025-10-14
BR112018006820A2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
MX2021007006A (en) Humanised anti kallikrein-2 antibody.
DOP2023000165A (en) CD3 BINDING ANTIBODIES
ECSP18073836A (en) BINDING MOLECULES TO BCMA AND METHODS OF USING THEM
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2024005027A (en) Cd3 binding antibodies.
UY35964A (en) HUMAN ANTIBODIES FOR PD? 1
CO2018009995A2 (en) Binding proteins and methods of use thereof
ECSP18096095A (en) ALPHA-SINUCLEIN ANTIBODIES AND USES OF THEM
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
DOP2017000031A (en) ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT, A PHARMACEUTICAL COMPOSITION AND USE
EA201791706A1 (en) ICOS BINDING PROTEINS
MX394459B (en) ANTI-LAG3 ANTIBODIES AND THEIR USES.
AR104280A1 (en) COMBINATION THERAPY WITH COAGULATION FACTORS AND MULTI-SPECIFIC ANTIBODIES
BR112016030965A2 (en) VEHICLE-ANTIBOD COMPOSITIONS AND MANUFACTURING METHODS AND USE THEREOF
AR101400A1 (en) INDIVIDUAL CHAIN INDIVIDUAL CHAIN ANTIBODY CONSTRUCTION WITH IMPROVED FABRIC DISTRIBUTION
BR112016016916A8 (en) use of an antibody that binds to active plasma kallikrein for treatment of hereditary angiodema (hae)
CY1117214T1 (en) COMPOSITION FOR CONTROLLED OVENTION STUDY
AR092737A1 (en) PHARMACEUTICAL COMBINATIONS THAT INCLUDE DUAL BINDERS OF ANGIOPOYETINA-2 / DLL4 AND ANTI-VEGF AGENTS, USE AND METHOD OF TREATMENT OF CANCER
UY37630A (en) PHARMACEUTICAL COMBINATION, KIT, GUEST CELL THAT PRODUCES IT AND ITS USE IN METHODS FOR CANCER TREATMENT
DOP2017000248A (en) RGMa UNION PROTEIN AND ITS USE
MX2018009499A (en) SPECIFIC MONOCLONAL ANTIBODIES OF EGFL6 AND METHODS OF USE.
ES2721935T3 (en) Anti-BAG3 antibodies for therapeutic use
MX2018004071A (en) POLYPEPTIDES AS ANTIBODIES AND USES OF THE SAME.
CO2023013550A2 (en) gucy2c binding polypeptide and uses thereof
MX2018013484A (en) NEW ANTI-TNFRSF21 ANTIBODIES AND MODES OF USE.